In Re: National Prescription Opiate Litigation

Track this case

Case overview

Case Number:

1:17-md-02804

See also:

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. June 07, 2022

    DEA Change In Opioid Policy Created Confusion, Judge Hears

    The U.S. Drug Enforcement Administration created "confusion" internally and with prescription drug distributors when it began requiring new suspicious order monitoring systems as opioid use surged around 2006, a San Francisco judge heard Tuesday in recorded testimony played during a bellwether opioid bench trial.

  2. June 02, 2022

    Walgreens Exec Faces Tough Queries From SF Opioid Judge

    A Walgreens executive took the stand in a bellwether opioid bench trial shortly after the city and county of San Francisco rested their case-in-chief Thursday, defending the pharmacy chain's compliance efforts and answering tough questions from the California federal judge presiding over the bench trial.

  3. June 02, 2022

    Panel Rejects Opioid MDL Expansion Despite 'Flood Of Cases'

    The Judicial Panel on Multidistrict Litigation rebuffed pleas from drugstore giants CVS Pharmacy, Walgreens and Walmart to rethink its surprise decision capping multidistrict opioid litigation, shrugging off predictions that opioid cases will spread chaotically in courts across the country.

  4. June 01, 2022

    SF Opioid Judge Told Higher Doses Increased Addiction

    Attorneys for the city of San Francisco sought to bolster their case Wednesday that Allergan, Teva, Walgreens and Anda illegally fueled the city's opioid epidemic by calling experts to testify that rising prescriptions and dosages allegedly pushed by the drug industry contributed to rising addiction rates.

  5. June 01, 2022

    SF Opioid Judge Irked At Allergan Argument Against Expert

    The federal judge presiding over a high-stakes bench trial on San Francisco's claim that Allergan, Teva and other entities fueled the city's opioid crisis expressed annoyance Tuesday at arguments from Allergan's counsel that an expert improperly lumped manufacturers together in concluding they drove loosened safety restrictions.

  6. May 27, 2022

    Opioid Judge Raiding Settlements For Atty Fees, 6th Circ. Told

    The Ohio federal judge supervising multidistrict opioid litigation is unlawfully "commandeering" cases outside the MDL by demanding fees for prominent plaintiffs lawyers from future opioid settlements, hundreds of local governments told the Sixth Circuit in a new petition.

  7. May 26, 2022

    Teva And Cephalon's Marketing Ignored Plea Deal, Judge Told

    Teva and Cephalon improperly peddled their painkiller Fentora even after Cephalon reached a 2008 plea agreement to resolve criminal claims it marketed a different opioid for unapproved uses, San Francisco's lawyer told the federal judge overseeing a bench trial on claims the companies and others illegally fueled the city's opioid epidemic.

  8. May 23, 2022

    DEA Draws Judge's Ire In Calif. Opioid Trial

    The federal judge overseeing a high-stakes trial related to San Francisco's opioid crisis said testimony from an ex-Actavis executive Monday about the U.S. Drug Enforcement Administration reminded him of the agency's flawed handling of an opioid concern in another case, saying the government had "failed" in that matter.

  9. May 19, 2022

    SF Fire Dept. Treats 7 Opioid Overdoses Daily, Judge Told

    A San Francisco Fire Department official testified in a bellwether opioid bench trial Thursday that opioid abuse has become so prevalent in the city that emergency responders now treat an average of seven overdoses daily, whereas public overdoses were a rare occurrence in the early 2000s.

  10. May 17, 2022

    Teva Unit Marketed Opioid For Off-Label Uses, Judge Hears

    Teva unit Cephalon saw sales of its opioid lollipop Actiq soar after it began marketing the product for non-FDA approved off-label uses, a judge heard Tuesday in recorded testimony from ex-Cephalon employees in a bellwether trial over claims the drugmaker and others illegally fueled San Francisco's opioid epidemic.